Cargando…
Onabotulinum Toxin A (Botox®) in the Treatment of Neurogenic Bladder Overactivity
Botulinum toxin (BT) is a potent presynaptic neuromuscular blocking agent which induces selective, reversible muscle weakness for months when injected intramuscularly. During recent years BT has revolutionized the treatment of previously intractable symptoms of detrusor overactivity. Based on a syst...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Kowsar
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614280/ https://www.ncbi.nlm.nih.gov/pubmed/23573462 http://dx.doi.org/10.5812/numonthly.1864 |
_version_ | 1782264819772030976 |
---|---|
author | Rohrsted, Malene Nordsten, Cecilie Bagi Bagi, Per |
author_facet | Rohrsted, Malene Nordsten, Cecilie Bagi Bagi, Per |
author_sort | Rohrsted, Malene |
collection | PubMed |
description | Botulinum toxin (BT) is a potent presynaptic neuromuscular blocking agent which induces selective, reversible muscle weakness for months when injected intramuscularly. During recent years BT has revolutionized the treatment of previously intractable symptoms of detrusor overactivity. Based on a systematic search of the PubMed database, a review of the current literature on the use of onabotulinum toxin A (Botox®) in the treatment of neurogenic detrusor overactivity is presented. Onabotulinum toxin A proved to be highly effective in the majority of studies, even though a wide range of injection techniques and dosages were described. The onset of the effect usually appeared before 2 weeks, and reached a peak within 2-6 weeks, with the clinical effect being maintained for approximately 6-8 months, or even longer. Depending on the dose, a number of patients developed high residual volume and clean intermittent self/helper catheterization (CIC) may become necessary. Only a few side effects were described, and intravesical onabotulinum toxin A injection seems to be well tolerated. However, details on injection technique, dose interval between injections, etc. are still under debate and only a few randomized, placebo controlled studies have been published. |
format | Online Article Text |
id | pubmed-3614280 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Kowsar |
record_format | MEDLINE/PubMed |
spelling | pubmed-36142802013-04-09 Onabotulinum Toxin A (Botox®) in the Treatment of Neurogenic Bladder Overactivity Rohrsted, Malene Nordsten, Cecilie Bagi Bagi, Per Nephrourol Mon Review Article Botulinum toxin (BT) is a potent presynaptic neuromuscular blocking agent which induces selective, reversible muscle weakness for months when injected intramuscularly. During recent years BT has revolutionized the treatment of previously intractable symptoms of detrusor overactivity. Based on a systematic search of the PubMed database, a review of the current literature on the use of onabotulinum toxin A (Botox®) in the treatment of neurogenic detrusor overactivity is presented. Onabotulinum toxin A proved to be highly effective in the majority of studies, even though a wide range of injection techniques and dosages were described. The onset of the effect usually appeared before 2 weeks, and reached a peak within 2-6 weeks, with the clinical effect being maintained for approximately 6-8 months, or even longer. Depending on the dose, a number of patients developed high residual volume and clean intermittent self/helper catheterization (CIC) may become necessary. Only a few side effects were described, and intravesical onabotulinum toxin A injection seems to be well tolerated. However, details on injection technique, dose interval between injections, etc. are still under debate and only a few randomized, placebo controlled studies have been published. Kowsar 2012-03-01 2012 /pmc/articles/PMC3614280/ /pubmed/23573462 http://dx.doi.org/10.5812/numonthly.1864 Text en Copyright © 2012 Kowsar M. P. Co. All rights reserved. http://creativecommons.org/licenses/by/3/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Rohrsted, Malene Nordsten, Cecilie Bagi Bagi, Per Onabotulinum Toxin A (Botox®) in the Treatment of Neurogenic Bladder Overactivity |
title | Onabotulinum Toxin A (Botox®) in the Treatment of Neurogenic Bladder Overactivity |
title_full | Onabotulinum Toxin A (Botox®) in the Treatment of Neurogenic Bladder Overactivity |
title_fullStr | Onabotulinum Toxin A (Botox®) in the Treatment of Neurogenic Bladder Overactivity |
title_full_unstemmed | Onabotulinum Toxin A (Botox®) in the Treatment of Neurogenic Bladder Overactivity |
title_short | Onabotulinum Toxin A (Botox®) in the Treatment of Neurogenic Bladder Overactivity |
title_sort | onabotulinum toxin a (botox®) in the treatment of neurogenic bladder overactivity |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614280/ https://www.ncbi.nlm.nih.gov/pubmed/23573462 http://dx.doi.org/10.5812/numonthly.1864 |
work_keys_str_mv | AT rohrstedmalene onabotulinumtoxinabotoxinthetreatmentofneurogenicbladderoveractivity AT nordstenceciliebagi onabotulinumtoxinabotoxinthetreatmentofneurogenicbladderoveractivity AT bagiper onabotulinumtoxinabotoxinthetreatmentofneurogenicbladderoveractivity |